<?xml version="1.0" encoding="UTF-8"?>
<p>Additionally, adverse event management (additional outpatient visits, emergency department [ED] evaluations, hospitalizations and additional medications, such as growth factors) was $14,801 vs. $24,594 for boceprevir and telaprevir respectively. In the boceprevir group, 6 patients received epoetin-α, 1 received filgrastim, 4 patients required additional outpatient visits and 1 patient required an ED evaluation. In the telaprevir group, 7 patients received epoetin-α, 1 received filgrastim, 3 patients required additional outpatient visits, 2 patients needed an ED evaluation and 2 patients were briefly hospitalized. On an ITT basis, total cost per SVR achieved was $44,329 for boceprevir vs. $57,115 for telaprevir (
 <xref rid="pone.0163945.t004" ref-type="table">Table 4</xref>).
</p>
